Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Zouboulis Christos C.; Okun Martin M.; Prens Errol P.; Gniadecki Robert; Foley Peter A.; Lynde Charles; Weisman Jamie; Gu Yihua; Williams David A.; Jemec Gregor B. E.

首页> 外文期刊>Journal of the American Academy of Dermatology >Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

【24h】

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

机译：中度至严重的HIDradenitis的患者的长期服用疗效，Suppurativa /痤疮逆变：3年的阶段开放标签扩展研究结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The optimal long-term dosing strategy for adalimumab (ADA) in hidradenitis suppurativa/acne inversa (HS) was evaluated by pooling the results of the PIONEER phase 3 trials and an open-label extension (OLE) study.

机译：背景：通过汇集先驱3试验的结果和开放标签延伸（OLE）研究，通过汇集HIDradenita iscapurativa /痤疮逆逆脉（HS）的AdAlimalab（ADA）的最佳长期给药策略。

著录项

来源
《Journal of the American Academy of Dermatology》 |2019年第1期|共10页
作者
Zouboulis Christos C.; Okun Martin M.; Prens Errol P.; Gniadecki Robert; Foley Peter A.; Lynde Charles; Weisman Jamie; Gu Yihua; Williams David A.; Jemec Gregor B. E.;
展开▼
作者单位

Brandenburg Med Sch Theodor Fontane Dessau Med Ctr Dept Dermatol Auenweg 38 D-06847 Dessau;

Ft HealthCare Ft Atkinson WI USA;

Erasmus Univ Med Ctr Rotterdam Dept Dermatol Rotterdam Netherlands;

Univ Copenhagen Bispebjerg Hosp Dept Dermatol Copenhagen Denmark;

Univ Melbourne St Vincents Hosp Melbourne Dept Med Dermatol Melbourne Vic Australia;

Lynde Ctr Dermatol &

Prob Med Res Markham ON Canada;

Adv Med Res PC Atlanta GA USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

Univ Copenhagen Dept Dermatol Zealand Univ Hosp Fac Hlth Sci Roskilde Denmark;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词
acne inversa; adalimumab; continuous; dose; hidradenitis suppurativa; longitudinal; long-term; weekly;

机译：痤疮inversa;adalimumab;连续;剂量;hidradenitis suppurativa;纵向;长期;每周;

相似文献

外文文献

1. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study [J] . Zouboulis Christos C., Okun Martin M., Prens Errol P., Journal of the American Academy of Dermatology . 2019,第1期

机译：中度至严重的HIDradenitis的患者的长期服用疗效，Suppurativa /痤疮逆变：3年的阶段开放标签扩展研究结果
2. Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris [J] . Linda Stein Gold, Sunil Dhawan, Jonathan Weiss, The Journal of Clinical and Aesthetic Dermatology . 2019,第10期

机译：开放标签扩展研究评估FMX101 4％米诺环菌泡沫的长期安全性和功效，用于中度至严重的痤疮寻常症
3. Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study [J] . Fabio Guerriero, Anna Roberto, Maria Teresa Greco, Drug Design, Development and Therapy . 2016,第5期

机译：羟考酮-纳洛酮延长释放在中度至重度慢性非癌性疼痛老年患者中的长期疗效和安全性：一项为期52周的开放标签扩展研究
4. Efficacy Analysis of Preservative-Free Tafluprost and Timolol in Open-Angle Glaucoma and OHT Patients in a Phase-III Study [C] . GrundenJ., Lupinacci R. International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：在第三阶段研究中，在开放角度荧光眼和OHT患者中无防腐型TaFluprost和蒂莫尔的疗效分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4 Minocycline Foam for Moderate-to-Severe Acne Vulgaris [O] . Linda Stein Gold, Sunil Dhawan, Jonathan Weiss, 2019

机译：开放标签扩展研究评估FMX101 4％米诺环素泡沫对中度至重度寻常痤疮的长期安全性和有效性
7. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext [O] . A. L. Bakulev, A. V. Samtsov, A. A. Kubanov, 2019

机译：中度至严重牛皮癣患者的Netakimab的长期疗效和安全性。第二阶段开放标签扩展临床研究的结果BCD-085-2-EXT

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

摘要

著录项

相似文献

相关主题

期刊订阅